Status:
RECRUITING
The Efficacy of Vosevi in Treating DAA-experienced Patients
Lead Sponsor:
The Third Affiliated Hospital of Guangzhou Medical University
Conditions:
Chronic Hepatitis C
Medication Reaction
Eligibility:
All Genders
20-70 years
Brief Summary
Hepatitis C virus (HCV) infection remains a significant health problem in our country. The World Health Organization estimated that 71 million people worldwide had chronic HCV infection in 2015. And 3...
Eligibility Criteria
Inclusion
- Age of 20-70 years.
- Accepted the standard direct antiviral agent before
- HCV-RNA still positive
- Patients are administrated with once-daily oral Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir: 400mg/100mg/100mg) or Sofosbuvir/Velpatasvir (400mg/100mg) combined with ribavirin（500mg）twice a day treatment for rescue therapy.
- The good compliance of patients.
Exclusion
- Patients with antibodies against HIV, HBV, HDV, concretion or other forms of infectious disease.
- Evidence of hepatocellular carcinoma, decompensated liver disease, auto-immune hepatitis, or significant renal, cardiovascular, respiratory or neurological comorbidity.
- Concurrent treatment with glucocorticoids, cytotoxic drugs, nonsteroidal anti-inflammatory drugs, or immune modulators.
- Pregnancy.
Key Trial Info
Start Date :
February 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06180590
Start Date
February 28 2023
End Date
February 28 2027
Last Update
March 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China